The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial | Zendy

AI Assistant Blog Pricing

The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.